Back to Journals » Vascular Health and Risk Management » Volume 3 » Issue 1

Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors,  or both? Expectations from The ONTARGET  Trial Programme

       
Total article views   HTML views PDF downloads Totals
10,089 Dovepress* 7,255+ 348 7,603
PubMed Central* 2,834 148 2,982
Totals 10,089 496 10,585
*Since 15 March 2007
+Since July 2016

View citations on PubMed Central and Google Scholar